Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,520

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681

Molecular characterisation of pancreatic ductal adenocarcinoma withNTRKfusions and review of the literature

Allen, M. J., Zhang, A. X. W., Bavi, P. P., Kim, J. C., Jang, G. H., Kelly, D., Perera, S., Denroche, R., Notta, F., Wilson, J. M., et al. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207781 · Cited by 35

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Pham, N., Radulovich, N., Ibrahimov, E., Martins-Filho, S. N., Li, Q., Pintilie, M., Weiss, J., Raghavan, V., Cabanero, M., Denroche, R. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90049-1 · Cited by 33

KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment

Carpenter, E. S., Kadiyala, P., Elhossiny, A. M., Kemp, S. B., Li, J., Steele, N. G., Nicolle, R., Nwosu, Z. C., Freeman, J., Dai, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1421 · Cited by 32

Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy

Roger, É., Gout, J., Arnold, F., Beutel, A. K., Müller, M., Abaei, A., Barth, T. F. E., Rasche, V., Seufferlein, T. T. W., Perkhofer, L., et al. (2020) · Cells · doi:10.3390/cells9092110 · Cited by 31

Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study

Suurmeijer, J. A., Soer, E. C., Dings, M. P. G., Kim, Y., Strijker, M., Bonsing, B. A., Brosens, L. A. A., Busch, O. R., Groen, J. V., Halfwerk, J. B. G., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac272 · Cited by 30

Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years

Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 33

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

Lee, M. K. C., Grimmond, S. M., McArthur, G. A., & Sheppard, K. E. (2021) · Cancers · doi:10.3390/cancers13205136 · Cited by 30

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 31

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

Tsang, E. S., Csizmók, V., Williamson, L. M., Pleasance, E., Topham, J. T., Karasinska, J. M., Titmuss, E., Schrader, K. A., Yip, S. S. F., Tessier‐Cloutier, B., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00368-x · Cited by 26

Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives

Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28

Circulating EVs long RNA-based subtyping and deconvolution enable prediction of immunogenic signatures and clinical outcome for PDAC

Li, Y., Li, Y., Yu, S., Qian, L. M., Chen, K., Lai, H., Zhang, H., Li, Y., Zhang, Y., Gu, S., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.017 · Cited by 27

Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer

Aguirre, A. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1280 · Cited by 27

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer

Ostios-García, L., Villamayor, J., Garcia-Lorenzo, E., Viñal, D., & Feliú, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6775 · Cited by 25

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer

Sivapalan, L., Thorn, G. J., Gadaleta, E., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09387-6 · Cited by 26

Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma

Ecker, B. L., Tao, A. J., Janssen, Q. P., Walch, H. S., Court, C. M., Balachandran, V. P., Crane, C. H., D'Angelica, M. I., Drebin, J. A., Kingham, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3089 · Cited by 26

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients

Dalmasso, B., Puccini, A., Catalano, F., Borea, R., Iaia, M. L., Bruno, W., Fornarini, G., Sciallero, S., Rebuzzi, S. E., & Ghiorzo, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094709 · Cited by 25

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities

Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 25

Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model

Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 28

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 26

Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples

Semaan, A., Bernard, V., Lee, J. J., Wong, J., Huang, J. H., Swartzlander, D. B., Stephens, B. M., Monberg, M. E., Weston, B. R., Bhutani, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2667 · Cited by 25

Advances in the management of pancreatic ductal adenocarcinoma

O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450 · Cited by 23

Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Ayasun, R., Saridogan, T., Gaber, O., & Şahin, İ. H. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.001 · Cited by 22

Inter‐ and intra‐tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas

Hernandez, A. L., Wang, Y., Somerset, H., Keysar, S. B., Aisner, D. L., Marshall, C. B., Bowles, D. W., Karam, S. D., Raben, D., Jimeno, A., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22958 · Cited by 24

Genome‐wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis

Wei, T., Zhang, J., Li, J., Chen, Q., Zhi, X., Wei, T., Ma, J., Yang, J., Lou, Y., Ma, T., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12757 · Cited by 24

Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma

Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 25

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing

Paiella, S., Azzolina, D., Gregori, D., Malleo, G., Golan, T., Simeone, D. M., Davis, M., Vacca, P., Crovetto, A., Bassi, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100881 · Cited by 23

Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review

Seghers, A.-K., Cuyle, P.-J. A., & Cutsem, E. V. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00727-9 · Cited by 22

A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism

Li, M., Freeman, S. R., Franco‐Barraza, J., Cai, K. Q., Kim, A., Jin, S., Cukierman, E., & Ye, K. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122631 · Cited by 24

POLE gene hotspot mutations in advanced pancreatic cancer

Guenther, M., Veninga, V., Kumbrink, J., Haas, M., Westphalen, C. B., Krüger, S., Heinemann, V., Kirchner, T., Boeck, S. H., Jung, A., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2746-x · Cited by 22

Endoscopic ultrasound‐guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine

Ashida, R., & Kitano, M. (2022) · Digestive Endoscopy · doi:10.1111/den.14344 · Cited by 23

Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma

Hong, W.-F., Zhang, F., Wang, N., Bi, J.-M., Zhang, D.-W., Wei, L., Song, Z., Mills, G. B., Chen, M., Li, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101115 · Cited by 22

Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Pal, T., Schon, K. R., Astiazarán-Symonds, E., Balmañà, J., Foulkes, W. D., James, P. A., Klugman, S. D., Livinski, A. A., Mak, J. S., Ngeow, J. Y. Y., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101243 · Cited by 22

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Park, W., O'Connor, C. A., Chou, J. F., Hilmi, M., Tarcan, Z. C., Schwartz, C., Larsen, M., Homsi, R., Sivaprakasam, K., Umeda, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04299-5 · Cited by 24

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives

Stoof, J., Harrold, E. C., Mariottino, S., Lowery, M. A., & Walsh, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749490 · Cited by 21

ATM-Mutated Pancreatic Cancer

Martino, C., Pandya, D. S., Lee, R. D., Levy, G. H., Lo, T., Lobo, S., & Frank, R. C. (2019) · Pancreas · doi:10.1097/mpa.0000000000001461 · Cited by 21

Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management

Schreyer, D., Neoptolemos, J. P., Barry, S. T., & Bailey, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795735 · Cited by 19

RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition

Hunihan, L., Zhao, D., Lazowski, H., Li, M., Qian, Y., Abriola, L., Surovtseva, Y. V., Muthusamy, V., Tanoue, L. T., Rothberg, B. E. G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4291 · Cited by 19

Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets

Chen, K., Liu, X., Di, L., Liu, W., Wang, F., Yang, Y., & Tian, X. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab343 · Cited by 20

Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

Lellouche, L., Palmieri, L., Dermine, S., Brézault, C., Chaussade, S., & Coriat, R. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018539 · Cited by 19

SMAD4 and KRAS Status Shapes Cancer Cell–Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer

Lloyd, E. G., Jihad, M., Manansala, J. S., Li, W., Cheng, P. S. W., Teles, S. P., Mucciolo, G., Henríquez, J. A., Ashworth, S., Luo, W., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2330 · Cited by 18

Pancreatic organoids as cancer avatars for true personalized medicine

Gout, J., Ekizce, M., Roger, É., & Kleger, A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115642 · Cited by 20

Patient-derived xenograft models of BRCA-associated pancreatic cancers

Golan, T., Atias, D., Stossel, C., & Raitses‐Gurevich, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.010 · Cited by 18

The molecular landscape of pancreatic ductal adenocarcinoma

Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.010 · Cited by 21

Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival

Urbanova, M., Cihova, M., Buociková, V., Slopovský, J., Dubovan, P., Pinďák, D., Tomáš, M., García‐Bermejo, L., Rodríguez-Garrote, M., Earl, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115179 · Cited by 19

Pancreas cancer: Therapeutic trials in metastatic disease

Smithy, J. W., & O'Reilly, E. M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26359 · Cited by 17

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

Sarno, F., Tenorio, J. A., Perea, S., Medina, L., Pazo-Cid, R., Martel, I. J., García‐Carbonero, R., Feliú, J., Guillén‐Ponce, C., Lopez-Casas, P. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4026 · Cited by 17

Advances in Vaccine-Based Therapies for Pancreatic Cancer

McMillan, M. T., & Soares, K. C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01165-4 · Cited by 19

Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma

Chawla, A., Qadan, M., Castillo, C. F. F.-D., Wo, J. Y.-L., Allen, J. N., Clark, J. W., Murphy, J. E., Catalano, O. A., Ryan, D. P., Ting, D. T., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004585 · Cited by 17

Inherited Pancreatic Cancer Syndromes and High-Risk Screening

Biller, L. H., Wolpin, B. M., & Goggins, M. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.002 · Cited by 19

Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity

Sellner, F., Thalhammer, S., & Klimpfinger, M. (2022) · Cancers · doi:10.3390/cancers14061539 · Cited by 17

BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17

Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis

Fujita, Y., Matsuda, S., Sasaki, Y., Masugi, Y., Kitago, M., Yagi, H., Abe, Y., Shinoda, M., Tokino, T., Sakamoto, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14268 · Cited by 17

PD-L1 upregulation accompanied with epithelial–mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells

Song, N., Bai, M., Che, X., Li, Z., Jing, W., Li, C., Teng, Z., Qu, X., & Liu, Y. (2020) · Medical Oncology · doi:10.1007/s12032-020-01372-y · Cited by 16

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., et al. (2021) · Cancers · doi:10.3390/cancers13225758 · Cited by 16

Loss of FGFR4 promotes the malignant phenotype of PDAC

D’Agosto, S. L., Pezzini, F., Veghini, L., Delfino, P., Fiorini, C., Tane, G. D. T., Curatolo, A. D., Vicentini, C., Ferrari, G., Pasini, D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02432-5 · Cited by 15

NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer

Jung, K., Lee, S., Na, H. Y., Kim, J., Lee, J.-C., Hwang, J., Kim, J. W., & Kim, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-24732-2 · Cited by 15

Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer

Reißig, T. M., Tzianopoulos, I., Liffers, S.-T., Rosery, V., Guyot, M., Ting, S., Wiesweg, M., Kasper, S., Meister, P., Herold, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101539 · Cited by 15

The role of molecular testing in pancreatic cancer

Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Huffman, B. M., Feng, H., Parmar, K., Wang, J., Kapner, K. S., Kochupurakkal, B. S., Martignetti, D. B., Sadatrezaei, G., Abrams, T. A., Biller, L. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2005 · Cited by 15

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

Barzi, A., Weipert, C. M., Espenschied, C. R., Raymond, V. M., Wang‐Gillam, A., Nezami, M. A., Gordon, E. J., Mahadevan, D., & Mody, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1339302 · Cited by 15

Pancreatic ductal adenocarcinoma in the era of precision medicine

Zheng-Lin, B., & O'Reilly, E. M. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.01.005 · Cited by 16

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma

Cleary, J. M., Wolpin, B. M., Dougan, S. K., Raghavan, S., Singh, H., Huffman, B. M., Sethi, N. S., Nowak, J. A., Shapiro, G. I., Aguirre, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1367 · Cited by 16

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

Wattenberg, M. M., & Reiss, K. A. (2021) · Cancers · doi:10.3390/cancers13184716 · Cited by 15

Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought

Agostini, A., Orlacchio, A., Carbone, C., & Guerriero, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876291 · Cited by 14

Treatment of pancreatic cancer in 2022

Casolino, R., & Biankin, A. V. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2 · Cited by 15

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection

Dai, M., Jahanzaib, R., Liao, Y., Yao, F., Li, J., Teng, X., Chen, K., & Cheng, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1074538 · Cited by 15

Genomics-Enabled Precision Medicine for Cancer

Roos, A., & Byron, S. A. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_5 · Cited by 14

Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC

Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 17

Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma

Ecker, B. L., Court, C. M., Janssen, Q. P., Tao, A. J., D’Angelica, M. I., Drebin, J. A., Gonen, M., O’Reilly, E. M., Jarnagin, W. R., Wei, A. C., et al. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000212 · Cited by 13

An integrated somatic and germline approach to aid interpretation of germline variants of uncertain significance in cancer susceptibility genes

Schwartz, A., Manning, D. K., Koeller, D. R., Chittenden, A. B., Isidro, R. A., Hayes, C. P., Abraamyan, F., Manam, M. D., Dwan, M., Barletta, J. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942741 · Cited by 13

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report

Shin, J. E., An, H. J., Park, H. S., Kim, H., & Shim, B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976450 · Cited by 14

Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma

Lopez-Blazquez, C., Lacalle-González, C., Sanz-Criado, L., Otieno, M. O., García‐Foncillas, J., & Martínez‐Useros, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914979 · Cited by 15

Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

Pantaleo, A., Forte, G., Fasano, C., Signorile, M. L., Sanese, P., Marco, K. D., Nicola, E. D., Latrofa, M., Grossi, V., Disciglio, V., et al. (2023) · Cancers · doi:10.3390/cancers16010056 · Cited by 15

Advancements in Preclinical Models of Pancreatic Cancer

Salu, P., & Reindl, K. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002277 · Cited by 13

Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017

Ding, D., Javed, A. A., Cunningham, D., Teinor, J. A., Wright, M. J., Javed, Z. N., Wilt, C., Parish, L., Hodgin, M. B., Ryan, A., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.039 · Cited by 14

Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?

Kokkinos, J., Jensen, A., Sharbeen, G., McCarroll, J. A., Goldstein, D., Haghighi, K. S., & Phillips, P. A. (2021) · Cancers · doi:10.3390/cancers13102427 · Cited by 14

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case reportPreprint

Ardalan, B., Azqueta, J. I., England, J. S., & Eatz, T. A. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006108 · Cited by 13

Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

Yu, K. H., Park, J., Mittal, A., Abou‐Alfa, G. K., Dika, I. E., Epstein, A. S., Ilson, D. H., Kelsen, D. P., Ku, G. Y., Li, J., et al. (2022) · Cancer · doi:10.1002/cncr.34269 · Cited by 12

Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma

Hyun, S., & Park, D. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.08.064 · Cited by 11

Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier

Li, Y., Merker, J. D., Kshatriya, R., Trembath, D. G., Morrison, A. B., Kuhlers, P. C., Rashid, N. U., Yeh, J. J., & Gulley, M. L. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.07.002 · Cited by 12

Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

Al-Share, B. A., Hammad, N., & Diab, M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09948-w · Cited by 12

The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer

Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12

Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications

Ohara, Y., Liu, H., Moreno, P., Suzuki, S., & Hussain, S. P. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108946 · Cited by 11

The Achilles’ Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials

Siolas, D., Morrissey, C., & Oberstein, P. E. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000052 · Cited by 11

Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

Morales, M. G., Visa, L., Vázquez, E., Feliú, J., Shahi, P. K., Sáez, B. L., Hernández, B. L. D. S. V., Macarulla, T. M., & Sarrió, R. G. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03386-8 · Cited by 11

Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer

Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12

Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach

Rajesh, S., Cox, M. J., & Runau, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i31.5171 · Cited by 11

Genomic features of Chinese small cell lung cancer

Liu, J., Zhao, Z., Wei, S., Li, B., & Zhao, Z. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01255-3 · Cited by 11

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Gong, J., Thomassian, S., Kim, S., Gresham, G. K., Moshayedi, N., Ye, J. Y., Yang, J. C., Jacobs, J. P., Lo, S., Nissen, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19401-3 · Cited by 11

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission

Casolino, R., Mateo, J., de Vries, E. G. E., Johns, A. J., Courtot, M., Lawlor, R. T., Perdomo, S., Gray, S. W., Pérez-López, R., Turnbull, C., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00302-5 · Cited by 11

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

Lee, Y. S., Klomp, J. E., Stalnecker, C. A., Goodwin, C. M., Gao, Y., Droby, G. N., Vaziri, C., Bryant, K. L., Der, C. J., & Cox, A. D. (2023) · Genes & Cancer · doi:10.18632/genesandcancer.231 · Cited by 11

Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma

Li, X., Hou, W., Xiao, C., Yang, H., Zhao, C., & Cao, D. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00970-6 · Cited by 10

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience

Miao, R., Blue, K., Sommerer, K. R., Shah, A., Bottiglieri, S., Cueto, A. D., Berry, D. K., Ho, T. T., Hicks, J. K., & Kim, D. W. (2024) · Cancers · doi:10.3390/cancers16203447 · Cited by 12

Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives

Hashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 11

Primary and metastatic cellular landscapes in human pancreatic cancer

Steele, N. G., Sirihorachai, V. R., Elhossiny, A. M., Loveless, I. M., Kadiyala, P., Bonilla, M. E., Opsahl, E. L. L., Vargas, C. S., Donahue, K. L., Kemp, S. B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113012 · Cited by 11

Diagnostic value of digital droplet polymerase chain reaction and digital multiplexed detection of single-nucleotide variants in pancreatic cytology specimens collected by EUS-guided FNA

Cazacu, I. M., Semaan, A., Stephens, B. M., Swartzlander, D. B., Guerrero, P. A., Singh, B. S., Lungulescu, C. V., Dănciulescu, M., Harbiyeli, I. F. C., Streață, I., et al. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.09.051 · Cited by 10

Cell death in cancer in the era of precision medicine

Raschellà, G., Melino, G., & Gambacurta, A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0048-6 · Cited by 10

Upfront molecular profiling of pancreatic cancer patients – An idea whose time has come

Bhutani, M. S., Cazacu, I. M., Roy‐Chowdhuri, S., Maitra, A., & Pishvaian, M. J. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.017 · Cited by 10

DNA damage response and repair in pancreatic cancer development and therapy

Farnood, P. R., Pazhooh, R. D., Asemi, Z., & Yousefi, B. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103116 · Cited by 11

Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine

Aguirre, A. J., Carter, S. L., Camarda, N. D., Ghazani, A. A., Nowak, J. A., da Silva, A., Brais, L. K., Ragon, D. Y., McCabe, D., Marini, L., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3036 · Cited by 2

Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial

Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618

Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large‐Scale Chinese Cohort

Dong, M., Hua, J., Zc, M., Tang, R., Wei, M., Lv, Z., Liu, Y., Chen, K., Du, Q., Wang, W., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72083

Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657).

Aung, K. L., Fischer, S. E., Denroche, R., Jang, G. H., Dodd, A., Creighton, S., O'Kane, G. M., Albaba, H., Moura, S. L., Holter, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.211 · Cited by 2

Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network.

Poruk, K. E., Moran, A., Doctor, V., Elvin, J. A., Radhi, S., Loaiza‐Bonilla, A., Schink, J. C., & Markman, M. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4137 · Cited by 2